» Articles » PMID: 28288568

Deep Sequencing of HPV E6/E7 Genes Reveals Loss of Genotypic Diversity and Gain of Clonal Dominance in High-grade Intraepithelial Lesions of the Cervix

Overview
Journal BMC Genomics
Publisher Biomed Central
Specialty Genetics
Date 2017 Mar 15
PMID 28288568
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Human papillomavirus (HPV) is the carcinogen of almost all invasive cervical cancer and a major cause of oral and other anogenital malignancies. HPV genotyping by dideoxy (Sanger) sequencing is currently the reference method of choice for clinical diagnostics. However, for samples with multiple HPV infections, genotype identification is singular and occasionally imprecise or indeterminable due to overlapping chromatograms. Our aim was to explore and compare HPV metagenomes in abnormal cervical cytology by deep sequencing for correlation with disease states.

Results: Low- and high-grade intraepithelial lesion (LSIL and HSIL) cytology samples were DNA extracted for PCR-amplification of the HPV E6/E7 genes. HPV+ samples were sequenced by dideoxy and deep methods. Deep sequencing revealed ~60% of all samples (n = 72) were multi-HPV infected. Among LSIL samples (n = 43), 27 different genotypes were found. The 3 dominant (most abundant) genotypes were: HPV-39, 11/43 (26%); -16, 9/43 (21%); and -35, 4/43 (9%). Among HSIL (n = 29), 17 HPV genotypes were identified; the 3 dominant genotypes were: HPV-16, 21/29 (72%); -35, 4/29 (14%); and -39, 3/29 (10%). Phylogenetically, type-specific E6/E7 genetic distances correlated with carcinogenic potential. Species diversity analysis between LSIL and HSIL revealed loss of HPV diversity and domination by HPV-16 in HSIL samples.

Conclusions: Deep sequencing resolves HPV genotype composition within multi-infected cervical cytology. Biodiversity analysis reveals loss of diversity and gain of dominance by carcinogenic genotypes in high-grade cytology. Metagenomic profiles may therefore serve as a biomarker of disease severity and a population surveillance tool for emerging genotypes.

Citing Articles

Lightweight Low-Rank Adaptation Vision Transformer Framework for Cervical Cancer Detection and Cervix Type Classification.

Hong Z, Xiong J, Yang H, Mo Y Bioengineering (Basel). 2024; 11(5).

PMID: 38790335 PMC: 11118906. DOI: 10.3390/bioengineering11050468.


Comparison of four different human papillomavirus genotyping methods in cervical samples: Addressing method-specific advantages and limitations.

Siqueira J, Alves B, Castelo Branco A, Duque K, Teresa Bustamante-Teixeira M, Soares E Heliyon. 2024; 10(3):e25474.

PMID: 38327440 PMC: 10847660. DOI: 10.1016/j.heliyon.2024.e25474.


Human papillomavirus genotyping using next generation sequencing (NGS) in cervical lesions: Genotypes by histologic grade and their relative proportion in multiple infections.

Basiletti J, Valls J, Poklepovich T, Fellner M, Rol M, Alonso R PLoS One. 2022; 17(11):e0278117.

PMID: 36417453 PMC: 9683586. DOI: 10.1371/journal.pone.0278117.


Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America.

Correa R, Baena A, Valls J, Colucci M, Mendoza L, Rol M PLoS One. 2022; 17(7):e0272205.

PMID: 35905130 PMC: 9337688. DOI: 10.1371/journal.pone.0272205.


HPV Integration Site Mapping: A Rapid Method of Viral Integration Site (VIS) Analysis and Visualization Using Automated Workflows in CLC Microbial Genomics.

Shen-Gunther J, Cai H, Wang Y Int J Mol Sci. 2022; 23(15).

PMID: 35897706 PMC: 9331699. DOI: 10.3390/ijms23158132.


References
1.
Bravo I, Felez-Sanchez M . Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health. 2015; 2015(1):32-51. PMC: 4356112. DOI: 10.1093/emph/eov003. View

2.
Reuter J, Spacek D, Snyder M . High-throughput sequencing technologies. Mol Cell. 2015; 58(4):586-97. PMC: 4494749. DOI: 10.1016/j.molcel.2015.05.004. View

3.
Resnick R, Cornelissen M, Wright D, Eichinger G, Fox H, Ter Schegget J . Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst. 1990; 82(18):1477-84. DOI: 10.1093/jnci/82.18.1477. View

4.
Huh W, Ault K, Chelmow D, Davey D, Goulart R, Garcia F . Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015; 136(2):178-82. DOI: 10.1016/j.ygyno.2014.12.022. View

5.
Tamura K, Stecher G, Peterson D, Filipski A, Kumar S . MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013; 30(12):2725-9. PMC: 3840312. DOI: 10.1093/molbev/mst197. View